keyword
MENU ▼
Read by QxMD icon Read
search

Aflibercept

keyword
https://www.readbyqxmd.com/read/28341388/-real-life-visual-and-anatomic-outcomes-of-aflibercept-treatment-for-treatment-naive-patients-with-exudative-age-related-macular-degeneration
#1
M-V Duval, M-B Rougier, M-N Delyfer, F Combillet, J-F Korobelnik
Anti-VEGF therapies have revolutionized the treatment of neovascular age-related macular degeneration (AMD). PURPOSE: The goal of this study was to evaluate the "real life" visual and anatomical outcomes of aflibercept treatment for treatment-naive patients with exudative AMD. METHODS: This was a retrospective study of patients treated with aflibercept in the department of Ophthalmology at the University Hospital of Bordeaux between November 2013 and July 2015. The follow-up period varied from 3months to 2years...
March 21, 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28333879/intravitreal-aflibercept-injection-for-choroidal-neovascularization-due-to-presumed-ocular-histoplasmosis-syndrome-the-handle-study
#2
Brian W Toussaint, John W Kitchens, Dennis M Marcus, Daniel M Miller, Megan L Kingdon, Diana Holcomb, Ken Ivey
PURPOSE: To evaluate intravitreal aflibercept injection (IAI) in patients with presumed ocular histoplasmosis syndrome and choroidal neovascularization. METHODS: Open-label randomized Phase I/II study of IAI in patients with presumed ocular histoplasmosis syndrome-related choroidal neovascularization. Thirty-nine eyes from 39 patients were randomized in a 1:1 ratio to 2 groups. The Sustained Group eyes (n = 19) underwent monthly IAI for 3 months, then mandatory IAI every 2 months for 12 months (with an option for monthly PRN dosing, if needed)...
March 22, 2017: Retina
https://www.readbyqxmd.com/read/28332616/long-acting-protein-drugs-for-the-treatment-of-ocular-diseases
#3
Joy G Ghosh, Andrew A Nguyen, Chad E Bigelow, Stephen Poor, Yubin Qiu, Nalini Rangaswamy, Richard Ornberg, Brittany Jackson, Howard Mak, Tucker Ezell, Vania Kenanova, Elisa de la Cruz, Ana Carrion, Bijan Etemad-Gilbertson, Roxana Garcia Caro, Kan Zhu, Vinney George, Jirong Bai, Radhika Sharma-Nahar, Siyuan Shen, Yiqin Wang, Kulandayan K Subramanian, Elizabeth Fassbender, Michael Maker, Shawn Hanks, Joanna Vrouvlianis, Barrett Leehy, Debby Long, Melissa Prentiss, Viral Kansara, Bruce Jaffee, Thaddeus P Dryja, Michael Roguska
Protein drugs that neutralize vascular endothelial growth factor (VEGF), such as aflibercept or ranibizumab, rescue vision in patients with retinal vascular diseases. Nonetheless, optimal visual outcomes require intraocular injections as frequently as every month. Here we report a method to extend the intravitreal half-life of protein drugs as an alternative to either encapsulation or chemical modifications with polymers. We combine a 97-amino-acid peptide of human origin that binds hyaluronan, a major macromolecular component of the eye's vitreous, with therapeutic antibodies and proteins...
March 23, 2017: Nature Communications
https://www.readbyqxmd.com/read/28316836/comparison-of-progression-rate-of-retinal-pigment-epithelium-loss-in-patients-with-neovascular-age-related-macular-degeneration-treated-with-ranibizumab-and-aflibercept
#4
Juliana Wons, Magdalena A Wirth, Nicole Graf, Matthias D Becker, Stephan Michels
Purpose. Retinal pigment epithelium (RPE) loss in neovascular age-related macular degeneration (nAMD) seem to have a linear progression but might be influenced by the treatment. The purpose of the study is the comparison of RPE loss over three years in patients treated with intravitreal ranibizumab to patients who were switched to aflibercept. Methods. A retrospective analysis with 96 eyes switched to aflibercept was conducted. The progression rate of RPE loss was evaluated in patients who showed atrophy one year prior to switch (n = 17) or on switch date (n = 19)...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28315512/comments-to-clinical-experience-of-switching-anti-vegf-therapy-from-ranibizumab-to-aflibercept-in-age-related-choroidal-neovascularization
#5
Dan Călugăru, Mihai Călugăru
No abstract text is available yet for this article.
March 7, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28306392/effect-of-syringe-design-on-the-accuracy-and-precision-of-intravitreal-injections-of-anti-vegf-agents
#6
Elad Moisseiev, Jolene Rudell, Eric V Tieu, Glenn Yiu
PURPOSE: To evaluate the accuracy and precision of different syringe designs for intravitreal injection of anti-VEGF agents. METHODS: Volume output was measured from three syringe designs-1) 1.0 mL tuberculin syringe, 2) 1.0 mL syringe with low dead space plunger, and 3) 0.5 mL low-volume syringe-to deliver 50 µL of bevacizumab, ranibizumab, or aflibercept, each repeated four times by three different physicians for 108 total simulated injections. Volume output was calculated from difference in syringe weight before and after expelling the drug...
March 17, 2017: Current Eye Research
https://www.readbyqxmd.com/read/28301410/allergic-reaction-upon-intravitreal-administration-of-anti-vascular-endothelial-growth-factor-agents
#7
Gavin G Meredith, Paul A Schkade, Brian C Joondeph
PURPOSE: To describe the patient's allergic response to anti-vascular endothelial growth factor drugs after receiving intravitreal bevacizumab for choroidal neovascularization. METHODS: Clinical case report. RESULTS: Formal allergy evaluation revealed hypersensitivity to bevacizumab and ranibizumab, but not to pegaptanib or aflibercept. CONCLUSION: Bevacizumab and ranibizumab are derivatives of murine monoclonal antibodies, whereas pegaptanib is an aptamer and aflibercept is a fusion protein of human origin...
March 15, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/28297035/short-term-effects-of-early-switching-to-ranibizumab-or-aflibercept-in-diabetic-macular-edema-cases-with-non-response-to-bevacizumab
#8
Mohammed Ashraf, Ahmed A R Souka, Hassan ElKayal
BACKGROUND AND OBJECTIVES: To study the effect of early switching to ranibizumab (Lucentis; Genentech, South San Francisco, CA) or aflibercept (Eylea; Regeneron, Tarrytown, NY) in cases of diabetic macular edema (DME) that have shown no response to bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: A retrospective study involving 59 eyes of 45 patients with DME previously treated with bevacizumab. Patients were switched either to ranibizumab or aflibercept...
March 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28280634/erratum-to-osteonecrosis-of-the-jaw-associated-with-ziv-aflibercept
#9
(no author information available yet)
[This corrects the article on p. E81 in vol. 7, PMID: 28078129.].
February 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28279730/efficacy-of-aflibercept-eylea-%C3%A2-on-inhibition-of-human-vegf-in-vitro
#10
M Schicht, K Hesse, H Schröder, E Naschberger, W Lamprecht, F Garreis, F P Paulsen, L Bräuer
INTRODUCTION: Pathological formation of blood vessels plays a key role in the growth and metastasis of tumors and also in several serious ophthalmological diseases such as wet age-related macular degeneration (AMD) or diabetic retinopathy. In AMD treatment, aflibercept (tradename EYLEA(®)) is used to deactivate the underlying pathological neovascularisation. Aflibercept is a recombinant fusion protein which binds to vascular endothelial growth factor (VEGF) receptors, thereby inhibiting VEGF pathway activation...
March 7, 2017: Annals of Anatomy, Anatomischer Anzeiger: Official Organ of the Anatomische Gesellschaft
https://www.readbyqxmd.com/read/28270485/long-term-safety-and-efficacy-of-ziv-aflibercept-in-retinal-diseases
#11
Ahmad M Mansour, Mohammed Ashraf, Chintan J Dedhia, Abdulrazzak Charbaji, Ahmed A R Souka, Jay Chhablani
AIMS: To investigate the long-term safety of intravitreal ziv-aflibercept in eyes receiving six or more intravitreal injections of ziv-aflibercept, an off-label substitute to the approved aflibercept. METHODS: Consecutive patients with retinal disease receiving six or more of intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections were followed monthly in three centres. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution (logMar)) and central macular thickness (CMT) on spectral domain optical coherence tomography and monitoring for ocular inflammation, progression of lens opacities and intraocular pressure rise...
March 7, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28266609/incidence-and-risk-factors-of-retreatment-after-three-monthly-aflibercept-therapy-for-exudative-age-related-macular-degeneration
#12
Wataru Kikushima, Yoichi Sakurada, Seigo Yoneyama, Atsushi Sugiyama, Naohiko Tanabe, Atsuki Kume, Fumihiko Mabuchi, Hiroyuki Iijima
Though anti-vascular endothelial growth factor therapy has become the standard treatment for exudative age-related macular degeneration (AMD), retreatment after the initial loading injection is inevitable in most eyes with residual or recurrent exudative changes. In the present study, we studied 140 treatment naïve eyes with typical neovascular AMD (n = 71) or polypoidal choroidal vasculopathy (PCV) (n = 69) and investigated the incidence and risk factors of retreatment after 3-monthly intravitreal aflibercept injection for exudative AMD during the 12-month period...
March 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28260852/prolongation-of-injection-interval-after-switching-therapy-from-ranibizumab-to-aflibercept-in-japanese-patients-with-macular-edema-secondary-to-branch-retinal-vein-occlusion
#13
Mizuki Tagami, Ryuto Sai, Masahide Fukuda, Atsushi Azumi
PURPOSE: This study was conducted to investigate the outcome of switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) in daily practice. MATERIALS AND METHODS: This retrospective study enrolled 15 eyes in 15 Japanese patients with ME secondary to BRVO who had been receiving a pro re nata regimen of ranibizumab and had provided written informed consent to switch to aflibercept therapy...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28260851/anti-vegf-treatment-of-diabetic-macular-edema-in-clinical-practice-effectiveness-and-patterns-of-use-echo-study-report-1
#14
Kevin J Blinder, Pravin U Dugel, Sanford Chen, J Michael Jumper, John G Walt, David A Hollander, Lanita C Scott
PURPOSE: To evaluate the efficacy, safety, and injection frequency of vascular endothelial growth factor (VEGF) inhibitors as used in clinical practice for the treatment of diabetic macular edema. METHODS: Multicenter (10 sites), retrospective chart review in patients (n=156) who received ≥3 anti-VEGF injections. Data collected for ≥6 months after the first injection included Snellen best-corrected visual acuity (BCVA) and central retinal thickness (CRT) by time-domain or spectral-domain optical coherence tomography (TD-OCT or SD-OCT)...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28259869/one-year-outcomes-of-a-treat-and-extend-regimen-of-aflibercept-for-exudative-age-related-macular-degeneration
#15
Akiko Yamamoto, Annabelle A Okada, Makiko Nakayama, Yumiko Yoshida, Hiroaki Kobayashi
PURPOSE: The aim of this study was to investigate the 1-year outcomes of treat-and-extend aflibercept for exudative age-related macular degeneration (AMD) in Japan. PROCEDURES: Clinical records of 67 patients (67 eyes) were reviewed. Monthly aflibercept was administered until resolution of exudation and maximal reduction of pigment epithelial detachment. Injection intervals were extended by 2-week units up to 12 weeks if no exudation was observed and shortened for recurrence...
March 4, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28259285/serum-and-tissue-markers-in-colorectal-cancer-state-of-art
#16
REVIEW
Massimiliano Berretta, Lara Alessandrini, Chiara De Divitiis, Guglielmo Nasti, Arben Lleshi, Raffaele Di Francia, Gaetano Facchini, Carla Cavaliere, Carlo Buonerba, Vincenzo Canzonieri
Colorectal cancer (CRC) represents one of the most commonly diagnosed cancers worldwide. It is the second leading cause of cancer death in Western Countries. In the last decade, the survival of patients with metastatic CRC has improved dramatically. Due to the advent of new drugs (irinotecan and oxaliplatin) and target therapies (i.e. bevacizumab, cetuximab, panitumab, aflibercept and regorafenib), the median overall survival has risen from about 12 mo in the mid nineties to 30 mo recently. Molecular studies have recently widened the opportunity for testing new possible markers, but actually, only few markers can be recommended for practical use in clinic...
March 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28257068/effects-of-ranibizumab-and-aflibercept-on-human-m%C3%A3-ller-cells-and-photoreceptors-under-stress-conditions
#17
Weiyong Shen, Belinda Yau, So-Ra Lee, Ling Zhu, Michelle Yam, Mark C Gillies
Anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of retinal vascular diseases. However, constitutive VEGF also acts as a trophic factor on retinal nonvascular cells. We have studied the effects of aflibercept and ranibizumab on human Müller cells and photoreceptors exposed to starvation media containing various concentrations of glucose, with or without CoCl2-induced hypoxia. Cell survival was assessed by calcein-AM cell viability assays. Expression of heat shock proteins (Hsp) and redox proteins thioredoxin 1 and 2 (TRX1, TRX2) was studied by Western blots...
March 1, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28256961/gemcitabine-mono-therapy-versus-gemcitabine-plus-targeted-therapy-in-advanced-pancreatic-cancer-a-meta-analysis-of-randomized-phase-iii-trials
#18
Alessandro Ottaiano, Monica Capozzi, Chiara De Divitiis, Alfonso De Stefano, Gerardo Botti, Antonio Avallone, Salvatore Tafuto
BACKGROUND: Prognosis of advanced pancreatic cancer is dismal and the novel targeted therapies, albeit successfully used to treat many advanced tumors, have shown modest results. We performed a meta-analysis in order to quantify the effect size on survival of adding targeted therapy to single agent gemcitabine. METHODS: Randomized phase III trials comparing gemcitabine mono-therapy versus gemcitabine plus a targeted agent in first-line treatment of advanced pancreatic cancer designed on survival as primary outcome were selected...
March 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28251077/the-effects-of-anti-vascular-endothelial-growth-factor-agents-on-human-retinal-pigment-epithelial-cells-under-high-glucose-conditions
#19
Jong Rok Oh, Jung Woo Han, Yoon Kyung Kim, Young-Hoon Ohn, Tae Kwann Park
AIM: To investigate the effects of high glucose levels and anti-vascular endothelial growth factor (VEGF) agents (bevacizumab, ranibizumab and aflibercept) on retinal pigment epithelium (RPE) cells. METHODS: ARPE-19 cells were cultured at different glucose levels (5.5 mmol/L, 25 mmol/L, and 75 mmol/L). Cell viability was evaluated by MTT assay at 3d after treatment with D-glucose. Cell migration ability was measured by wound healing assay at 3d. A cell death detection kit was used to assess apoptosis at 3 and 14d...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28243059/erratum-worsening-anatomic-outcomes-following-aflibercept-for-neovascular-age-related-macular-degeneration-in-eyes-previously-well-controlled-with-ranibizumab-corrigendum
#20
(no author information available yet)
[This corrects the article on p. 1053 in vol. 10, PMID: 27354759.].
2017: Clinical Ophthalmology
keyword
keyword
1772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"